MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.75 -1.83

Buy Sell

Overview

Share price change

24h

Current

Min

3.73

Max

3.89

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+219.61% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-38M 217M
Previous open	5.58
Previous close	3.75

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 sty 2026, 23:29 UTC

Hot Stocks

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 sty 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 sty 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 sty 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

16 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

16 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 sty 2026, 21:48 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 sty 2026, 21:41 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 sty 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 sty 2026, 20:44 UTC

Earnings

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 sty 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 sty 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 sty 2026, 19:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 sty 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 sty 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 sty 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 sty 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 sty 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 sty 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sty 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 sty 2026, 16:32 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 sty 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

219.61% upside

12 Months Forecast

Average 13.2 USD 219.61%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.